Last reviewed 2026-04-22 · How we verify

KAD-1229

KAD-1229 is a potassium channel opener that relaxes vascular smooth muscle to reduce blood pressure.

KAD-1229 is a potassium channel opener that relaxes vascular smooth muscle to reduce blood pressure. Used for Hypertension.

At a glance

Mechanism of action

KAD-1229 activates ATP-sensitive potassium channels in vascular smooth muscle cells, leading to hyperpolarization and relaxation of the vessel wall. This results in vasodilation and a reduction in peripheral vascular resistance, thereby lowering blood pressure. The drug is designed for oral administration in the treatment of hypertension.

Approved indications

• Hypertension

Common side effects

• Headache
• Dizziness
• Palpitations
• Fluid retention

Key clinical trials

• A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants (PHASE1)
• Pharmacokinetic and Pharmacodynamic Study of Glufast Tablets 10mg(Mitiglinide) (PHASE4)
• Post-marketing Clinical Trial of KAD-1229 in Patients With Type 2 Diabetes Mellitus (PHASE4)
• Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015) (PHASE3)
• Efficacy and Safety of Mitiglinide vs Acarbose in Patients With Type 2 Diabetes Mellitus (PHASE4)
• Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes (PHASE4)
• Long-term Study of KAD-1229 in Type 2 Diabetes Patients (PHASE3)
• Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogues in Type 2 Diabetes (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.